RAICHEM GLUCOSE UV REAGENT

K012668 · Hemagen Diagnostics, Inc. · CFR · Oct 15, 2001 · Clinical Chemistry

Device Facts

• Record ID: K012668
• Device Name: RAICHEM GLUCOSE UV REAGENT
• Applicant: Hemagen Diagnostics, Inc.
• Product Code: CFR · Clinical Chemistry
• Decision Date: Oct 15, 2001
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.1345
• Device Class: Class 2

Intended Use

This reagent is for the quantitative enzymatic determination of glucose in serum or plasma. For in vitro diagnostic use only.

Device Story

Raichem® Glucose UV Reagent is an in vitro diagnostic reagent used for the quantitative enzymatic determination of glucose levels in human serum or plasma samples. The device utilizes an enzymatic reaction to measure glucose concentration, providing results that assist clinicians in the diagnosis and management of carbohydrate metabolism disorders, including diabetes mellitus and hypoglycemia. It is intended for professional use in clinical laboratory settings. The reagent is processed using standard laboratory instrumentation capable of UV spectrophotometric analysis. Results are interpreted by healthcare professionals to inform clinical decision-making regarding patient metabolic status.

Clinical Evidence

No clinical data provided; bench testing only.

Technological Characteristics

Enzymatic UV reagent for glucose determination. Operates via spectrophotometric analysis of serum or plasma samples. In vitro diagnostic reagent format.

Indications for Use

Indicated for the quantitative enzymatic determination of glucose in human serum or plasma for in vitro diagnostic use.

Regulatory Classification

Identification

A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.

Special Controls

*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized eagle with three lines forming its body and wings. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the eagle.

OCT 1 5 2001

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Jose A. Montanez Offical Corresponent Hemagen Diagnostics, Inc. 9033 Red Branch Road Columbia, MD 21045

k012668 Re:

Trade/Device Name: Raichem® Glucose UV Reagent Regulation Number: 21 CFR 862.1345 Regulation Name: Glucose test system Regulatory Class: Class II Product Code: CFR Dated: August 8, 2001 Received: August 13, 2001

## Dear Mr. Montanez:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

Page 2 -

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed nredicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and 1 additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrb/dsma/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known): K012668

Device Name: Raichem® Glucose UV Reagent

Indications For Use: This reagent is for the quantitative enzymatic determination of glucose in serum or plasma. For in vitro diagnostic use only.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Kesia Alexande for Sean Cooper
(Division Sign-Off)
Division of Clinical Laboratory Devices

510(k) Number KO12168

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter Use___

(Optional Format 1-2-96)